Cover Image
市場調查報告書

中國的Rosuvastatin市場分析

Investigation Report on China's Rosuvastatin Market, 2018-2022

出版商 China Research and Intelligence 商品編碼 333488
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Rosuvastatin市場分析 Investigation Report on China's Rosuvastatin Market, 2018-2022
出版日期: 2018年11月29日 內容資訊: 英文 30 Pages
簡介

中國的Rosuvastatin市場年度銷售額,從2007年的200萬人民幣,到2014年達6億7,200萬人民幣,以139%的年複合成長率成長。今後數年,預計維持這樣的成長。

本報告提供中國的Rosuvastatin市場相關調查分析、市場規模、市場佔有率、零售價格、主要製造商、市場預測等相關的系統性資訊。

第1章 Rosuvastatin的相關概念

  • 適應
  • 全球市場銷售情形

第2章 中國的Rosuvastatin的市場簡介

  • 中國的Rosuvastatin的專利、核準情況
  • 主要製造商
  • 市場規模

第3章 中國的Rosuvastatin銷售分析

  • 銷售額
  • 銷售數量

第4章 中國的Rosuvastatin主要廠商的市場佔有率分析

  • 市場佔有率:各銷售額
  • 市場佔有率:各銷售數量

第5章 中國的Rosuvastatin的各劑型分析

  • 市場佔有率 (各劑型) :各銷售額
  • 市場佔有率 (各劑型) :各銷售數量

第6章 中國的Rosuvastatin的醫院用標準價格

  • IPR Pharmaceuticals
  • Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd.
  • Nanjing Chia Tai Tianqing
  • Zhejiang Jingxin Pharmaceutical Co., Ltd
  • Lunan Better Pharmaceutical Co., Ltd

第7章 中國市場的Rosuvastatin的主要製造商

  • Lunan Better Pharmaceutical Co., Ltd
  • Nanjing Chia Tai Tianqing
  • Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd.
  • Zhejiang Jingxin Pharmaceutical Co., Ltd
  • AstraZeneca plc.

第8章 中國的Rosuvastatin的市場預測

  • 市場規模的預測
  • 競爭情形的預測

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1811353

Description

Rosuvastatin was first developed by Japanese company Shionogi & Co., Ltd. in the late 1980s. In Jun. 1998, Shionogi & Co., Ltd. transferred the right to develop, market and sell Rosuvastatin worldwide to AstraZeneca. The development code of Rosuvastatin by AstraZeneca is ZD-4522. Rosuvastatin was first approved in the Netherlands on Nov. 7, 2002, approved by the Health Council of Canada in Feb. 2003, and by the FDA on Aug. 12, 2003. The trade name of AstraZeneca's branded Rosuvastatin is Crestor.

After Rosuvastatin was launched, its sales value grew sharply. Rosuvastatin has become a key product of statins. In 2012, Rosuvastatin became the number one lipid-lowering drug in the world with a sales value of USD 6.2 billion.

With the improvement of living standards and the change in diet, from 1978 to 2018, Chinese people's blood lipid levels kept rising, and the incidence of dyslipidemia increased significantly. The overall incidence of dyslipidemia in Chinese adults is up to about 40%. As dyslipidemia is a major cause of the development of coronary heart disease, strokes and other atherosclerotic lesions, active treatment of hyperlipidemia can reduce the incidence of these diseases. In China, Rosuvastatin is used to treat primary hypercholesterolemia (Type IIa, including heterozygous familial hypercholesterolemia) or mixed dyslipidemia (Type IIb) that cannot be properly controlled via diet control and non-drug treatments (e.g. sports therapy and weight loss). In the treatment of homozygous familial hypercholesterolemia, it complements the diet control and other lipid-lowering measures (such as LDL removal), or serves as an alternative when these measures do not work.

According to CRI, Rosuvastatin has been growing rapidly since it entered China, with its sales revenue increasing from less than CNY 2 million in 2007 to more than CNY 1.1 billion in 2017. At present, China's Rosuvastatin market is dominated by IPR PHARMACEUTICALS INC. (ASTRAZENECA), Lunan Better Pharmaceutical Co., Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd., Zhejiang Jingxin Pharmaceutical Co., Ltd., etc. Pfizer has the largest market share by sales value which was about 67% in 2017.

It is expected that as more Chinese people suffer from hyperlipidemia, China's Rosuvastatin market will continue to grow in the next few years.

Topics Covered:

  • Situation of hyperlipidemia in China
  • Market size of Rosuvastatin in China
  • Competitive landscape of China's Rosuvastatin market
  • Prices of Rosuvastatin in China
  • Prospect of China's Rosuvastatin market from 2018 to 2022

Table of Contents

Table of Contents

1 Relevant Concepts of Rosuvastatin

  • 1.1 Indications for Rosuvastatin
  • 1.2 Development of Rosuvastatin in China
  • 1.3 Patents and Government Approval on Rosuvastatin in China

2 Sales of Rosuvastatin in China, 2013-2017

  • 2.1 Sales Value of Rosuvastatin
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Rosuvastatin
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Rosuvastatin by Dosage Form in China, 2013-2017
    • 2.3.1 Tablets
    • 2.3.2 Capsules

3 Analysis on Major Rosuvastatin Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Rosuvastatin Manufacturers
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 IPR PHARMACEUTICALS INC.(ASTRAZENECA)
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Rosuvastatin by IPR PHARMACEUTICALS INC.(ASTRAZENECA) in China
  • 3.3 Lunan Better Pharmaceutical Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Rosuvastatin by Lunan Better Pharmaceutical Co., Ltd. in China
  • 3.4 Zhejiang Jingxin Pharmaceutical Co., Ltd.
  • 3.5 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.
  • 3.6 Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd.

4 Prices of Rosuvastatin in China, 2017-2018

  • 4.1 IPR PHARMACEUTICALS INC.(ASTRAZENECA)(Crestor)
  • 4.2 Lunan Better Pharmaceutical Co., Ltd. (Ruizhi)
  • 4.3 Zhejiang Jingxin Pharmaceutical Co., Ltd. (Jingnuo)
  • 4.4 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (Tuotuo)
  • 4.5 Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd. (Shufutan)

5 Prospect of China's Rosuvastatin Market, 2018-2022

  • 5.1 Forecast on Market Size
  • 5.2 Forecast on Market Trend

Selected Charts

  • Chart Government Approval of Rosuvastatin in China
  • Chart Sales Value of Rosuvastatin in China, 2013-2017
  • Chart Sales Value of Rosuvastatin in Parts of China, 2013-2017
  • Chart Sales Volume of Rosuvastatin in China, 2013-2017
  • Chart Sales Volume of Rosuvastatin in Parts of China, 2013-2017
  • Chart Sales Value of Rosuvastatin Tablets in China, 2013-2017
  • Chart Sales Value of Rosuvastatin Capsules in China, 2013-2017
  • Chart Market Share of Top 5 Rosuvastatin Manufacturers by Sales Value, 2013-2017
  • Chart Market Share of Top 5 Rosuvastatin Manufacturers by Sales Volume, 2013-2017
  • Chart Sales Value of Rosuvastatin by IPR PHARMACEUTICALS INC.(ASTRAZENECA), 2013-2017
  • Chart Sales Volume of Rosuvastatin by IPR PHARMACEUTICALS INC.(ASTRAZENECA), 2013-2017
  • Chart Sales Value of Rosuvastatin by Lunan Better Pharmaceutical Co., Ltd., 2013-2017
  • Chart Sales Volume of Rosuvastatin by Lunan Better Pharmaceutical Co., Ltd., 2013-2017
  • Chart Sales Value of Rosuvastatin by Zhejiang Jingxin Pharmaceutical Co., Ltd., 2013-2017
  • Chart Sales Value of Rosuvastatin by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., 2013-2017
  • Chart Prices of Rosuvastatin (Crestor) by IPR PHARMACEUTICALS INC.(ASTRAZENECA) in Parts of China, 2017-2018
  • Chart Prices of Rosuvastatin (Ruizhi) by Lunan Better Pharmaceutical Co., Ltd. in Parts of China, 2017-2018
  • Chart Prices of Rosuvastatin (Jingnuo) by Zhejiang Jingxin Pharmaceutical Co., Ltd. in Parts of China, 2017-2018
  • Chart Prices of Rosuvastatin (Tuotuo) by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. in Parts of China, 2017-2018
  • Chart Prices of Rosuvastatin (Shufutan) by Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd. in Parts of China, 2017-2018
  • Chart Forecast on Sales Value of Rosuvastatin in China, 2018-2022
Back to Top